EcoDrugPlus

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSHCOG00000004543
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSHCOG00000016868
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSHCOG00000013457
Gene Symbol: YES1
4 Cross references
208 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSHCOG00000019333
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSHCOG00000001894
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSHCOG00000009476
Gene Symbol: ADORA1
1 Cross references
204 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSHCOG00000009692
Gene Symbol: ADORA1B
1 Cross references
173 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSHCOG00000014390
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSHCOG00000005571
Gene Symbol: ADORA2AA
1 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSHCOG00000010020
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSHCOG00000001344
Gene Symbol: ADORA3
3 Cross references
145 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSHCOG00000008471
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).